The trial was conducted by Covance, and involved 74 healthy volunteers enrolled in the UK. The primary objective of this Phase I clinical trial was to demonstrate that POL6326 was safe and well tolerated.
Additional tests also confirmed the efficacy of POL6326 in the mobilization of HSCs and supported the hypothesis that it might also have applications in other indications such as tissue repair.
POL6326 is a potent, selective and reversible CXCR4 inhibitor belonging to a novel drug class based on Polyphor’s proprietary Protein Epitope Mimetics Technology.
Jean-Pierre Obrecht, CEO of Polyphor, said: “This study further confirmed the initial efficacy of POL6326 in humans and demonstrated the rapid, predictable onset of HSC mobilization over several hours. We are delighted with these results which give us confidence that POL6326 could enable the mobilization, collection and processing of HSCs within one day – a clear potential benefit for patients, donors and the clinical staff.”